The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH

PHASE4CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions
BPH (Benign Prostatic Hyperplasia)
Interventions
DRUG

Silodosin

Silodosin is an α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieve the dynamic obstruction of bladder outlet, and improve the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule,1 capsule/time, bid, after breakfast and dinner.

DRUG

Tamsolusin

Tamsulosin is an α1A-adrenergic receptor blocker which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.

Trial Locations (6)

Unknown

The First Affiliated Hospital of Anhui Medical University, Hefei

Wuhan Center Hospital, Wuhan

Wuhan No.1 Hospital, Wuhan

The Second Affiliated Hospital of Suzhou University, Suzhou

Beijing Tongren Hospital, Capital Medical University, Beijing

Ciivil Aviation General Hospital, Beijing

All Listed Sponsors
lead

Shanghai Huilun Pharmaceutical Co., Ltd.

INDUSTRY